PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.83%
Revenue growth above 1.5x AVGO's 6.13%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
21.53%
Gross profit growth above 1.5x AVGO's 12.70%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
24.20%
EBIT growth 50-75% of AVGO's 37.52%. Martin Whitman would suspect suboptimal resource allocation.
24.20%
Operating income growth at 50-75% of AVGO's 35.29%. Martin Whitman would doubt the firm’s ability to compete efficiently.
21.13%
Net income growth at 75-90% of AVGO's 27.27%. Bill Ackman would press for improvements to catch or surpass competitor performance.
20.00%
EPS growth at 50-75% of AVGO's 27.17%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
22.45%
Diluted EPS growth at 75-90% of AVGO's 26.67%. Bill Ackman would expect further improvements in net income or share count reduction.
-0.16%
Share reduction while AVGO is at 0.34%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.04%
Reduced diluted shares while AVGO is at 0.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.85%
Dividend reduction while AVGO stands at 11.29%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
33.45%
OCF growth above 1.5x AVGO's 9.08%. David Dodd would confirm a clear edge in underlying cash generation.
33.18%
FCF growth above 1.5x AVGO's 9.69%. David Dodd would verify if the firm’s strategic investments yield superior returns.
2045.22%
10Y revenue/share CAGR above 1.5x AVGO's 395.49%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1056.95%
5Y revenue/share CAGR above 1.5x AVGO's 115.85%. David Dodd would look for consistent product or market expansions fueling outperformance.
364.17%
3Y revenue/share CAGR above 1.5x AVGO's 69.86%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
9129.58%
10Y OCF/share CAGR above 1.5x AVGO's 590.26%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
2001.82%
5Y OCF/share CAGR above 1.5x AVGO's 123.17%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
726.15%
3Y OCF/share CAGR above 1.5x AVGO's 53.88%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
9801.56%
Net income/share CAGR above 1.5x AVGO's 751.52% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
3624.74%
5Y net income/share CAGR above 1.5x AVGO's 1111.68%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
685.25%
3Y net income/share CAGR above 1.5x AVGO's 95.35%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
971.24%
10Y equity/share CAGR in line with AVGO's 944.78%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
399.42%
5Y equity/share CAGR above 1.5x AVGO's 142.50%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
164.09%
3Y equity/share CAGR similar to AVGO's 166.34%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
90.49%
Below 50% of AVGO's 1592.86%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
-0.36%
Negative 5Y dividend/share CAGR while AVGO stands at 71.40%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-0.13%
Negative near-term dividend growth while AVGO invests at 38.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
23.66%
AR growth is negative/stable vs. AVGO's 73.85%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
11.02%
Inventory growth well above AVGO's 8.41%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
17.26%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
14.53%
BV/share growth above 1.5x AVGO's 2.77%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.59%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
10.34%
R&D growth drastically higher vs. AVGO's 0.85%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
9.13%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.